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Inﬂammatory response plays an important role in the pathogenesis of secondary brain injury after traumatic brain injury (TBI).
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor that plays a crucial role in cytoprotection against
inﬂammation. The present study investigated the role of Nrf2 in the cerebral upregulation of NF-κB activity, proinﬂammatory
cytokine, and ICAM-1 after TBI. Wild-type Nrf2 (+/+) and Nrf2 (−/−)-deﬁcient mice were subjected to a moderately severe
weight-drop impact head injury. Electrophoretic mobility shift assays (EMSAs) were performed to analyze the activation of
nuclear factor kappa B (NF-κB). Enzyme-linked immunosorbent assays were performed to quantify the production of tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Immunohistochemistry staining experiments were
performedtodetecttheexpressionofintercellularadhesionmolecule-1(ICAM-1).Nrf2(−/−)micewereshowntohavemoreNF-
κB activation, inﬂammatory cytokines TNF-α,I L - 1 β and IL-6 production, and ICAM-1 expression in brain after TBI compared
with their wild-type Nrf2 (+/+) counterparts. The results suggest that Nrf2 plays an important protective role in limiting the
cerebral upregulation of NF-κB activity, proinﬂammatory cytokine, and ICAM-1 after TBI.
Copyright © 2008 Wei Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cerebral inﬂammation plays an important role in the patho-
genesis of secondary brain injury following traumatic brain
injury (TBI) [1, 2]. Proinﬂammatory nuclear factor kappa
B( N F - κB) signaling pathway has been well documented in
previous studies of our laboratory [3, 4]. Increased levels
of inﬂammatory agents with the injured brain, including
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
interleukin-6 (IL-6), and intercellular adhesion molecule 1
(ICAM-1), are believed to contribute to the cerebral damage
[5].TheirmediatorNF-κBactivationenhancesthetranscrip-
tion of proinﬂammatory cytokines [6], and the cytokines are
known to in turn activate NF-κB[ 7]. The positive feedback
is believed to serve to amplify inﬂammatory signals and
exacerbate brain injury after TBI.
Recent researches have demonstrated that nuclear factor
erythroid 2-related factor 2 (Nrf2), a key transcription
factor that regulates the cellular antioxidant response, plays
a broader role in modulating acute inﬂammatory response
[8, 9]. Under basal conditions, Nrf2 is sequestered in the
cytoplasm by the cytosolic regulatory protein Keap1. In
conditionsofoxidativeorxenobioticstress,Nrf2translocates
from the cytoplasm to the nucleus, and sequentially binds
to a promoter sequence called the antioxidant response
element (ARE), resulting in a cytoprotective response which
is characterized by upregulation of a group of antioxidant
enzymes and decreased sensitivity to oxidative damage2 Mediators of Inﬂammation
[10–12]. These antioxidant enzymes have also been shown
to protect cells against acute inﬂammatory response [13].
Numerous studies have reported that Nrf2 plays a critical
role in counteracting inﬂammation in a variety of exper-
imental models. Nrf2 protects against allergen-mediated
airway inﬂammation [14], cigarette smoke-induced emphy-
sema [15], dextran sulfate sodium (DSS)-mediated colitis
[16], inﬂammation-mediated colonic tumorigenesis [17],
and inﬂammatory responses during skin wound healing
[18]. Furthermore, Nrf2 has also been reported as a crucial
regulatoroftheinnate immuneresponse andsurvivalduring
experimental sepsis [19]. In one of our previous studies, we
havedemonstratedthatTBIcouldinduceNrf2-AREpathway
activation in brain [20].
Therefore, it may be reasonable to postulate that Nrf2
playsanimportantroleinlimitingthecerebralinﬂammatory
response after TBI. In our study, we evaluated the inﬂuence
of Nrf2 genotype on the cerebral upregulation of NF-κB
activity, proinﬂammatory cytokine, and ICAM-1 after TBI.
2. MATERIALS AND METHODS
2.1. Animals
O u re x p e r i m e n t sw e r ec o n f o r m e dt oG u i d ef o rt h eC a r e
and Use of Laboratory Animals from National Institutes of
HealthandapprovedbytheAnimalCareandUseCommittee
of Nanjing University. Breeding pairs of Nrf2-deﬁcient ICR
mice were kindly provided by Dr. Thomas W. Kensler (Johns
Hopkins University, Baltimore, Md, USA). Homozygous
wild-type Nrf2 (+/+) and Nrf2 (−/−)-deﬁcient mice were
generated from inbred heterozygous Nrf2 (+/−)m i c e[ 10].
Genotypes of Nrf2 (+/+) and Nrf2 (−/−)m i c ew e r ec o n -
ﬁrmed by PCR ampliﬁcation of genomic DNA isolated from
the blood. PCR ampliﬁcation was carried out by using three
diﬀerent primers, 5 -TGGACGGGACTATTGAAGGCTG-
3  (sense for both genotypes), 5 -CGCCTTTTCAGTAGA-
TGGAGG-3  (antisense for wild-type ), and 5 -GCGGAT-
TGACCGTAATGGGATAGG-3  (antisense for LacZ). Age-
and weight-matched adult male mice (6–8 weeks, 28–32g)
were separated into four groups (n = 10 per group): group
I, sham wild-type (Nrf2 +/+); group II, injured wild-type
(Nrf2 +/+); group III, sham-deﬁcient (Nrf2 −/−); group
IV, injured-deﬁcient (Nrf2 −/−). The mice of sham and
injured groups were subjected to identical anesthetic alone
or experimental TBI, respectively. Animals were decapitated
at 24 hours following sham or injury. Five mice in each
group were sacriﬁced for electrophoretic mobility shift assay
(EMSA) and enzyme-linked immunosorbent assay (ELISA)
analysis and the others were for immunohistochemistry
study.
2.2. InductionofexperimentalTBI
The mouse model of TBI was employed as described
[21] with recent minor modiﬁcation [22]. The mice were
anesthetizedbyintraperitonealinjectionwithsodiumpento-
barbital(50mg/kg).Around,ﬂat,and6mmdiameterTeﬂon
impounder was centered between the ears and eyes. TBI was
Detected
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Figure 1: Schematic representation of the area taken for assay.
induced by a 100g weight dropped from a 12cm height
alongastainlesssteelstring,whichtranslatedinto1200g/cm.
Brain injury-induced apnea was then treated for 3 minutes
with 100% oxygen administration and chest compression to
stimulate the respiration. This model is generally associated
with 20% of mortality within the ﬁrst 5 minutes postinjury
and no delayed mortality was observed thereafter. After
operation procedures, the mice were returned to their cages.
Heart rate, arterial blood pressure, and rectal temperature
were monitored, and the rectal temperature was kept at 37 ±
0.5
◦C(physicalcooling if required) throughoutexperiments.
At the 24 hours following sham or injury, mice were sac-
riﬁced for sample collection. For EMSA and ELISA analyses,
mice were exsanguinated by cardiac puncture. Cortex tissue
was rapidly taken from the fresh brain at the site of lesion
(Figure 1), and stored in liquid nitrogen immediately. For
immunohistochemistry, mice were perfused with cold saline
(4◦C), followed by 4% neutral-buﬀered formalin. The cortex
tissue was taken, stored overnight in 4% neutral-buﬀered
formalin, and then embedded in paraﬃn.
2.3. NuclearproteinextractandEMSA
Nuclear protein was extracted and quantiﬁed as described
[23]. Brieﬂy, frozen brain samples were homogenized in
0.8mL ice-cold buﬀer A composed of 10mmol/L HEPES pH
7.9, 10mmol/L KCl, 2mmol/L MgCl2, 0.1mmol/L EDTA,
1mmol/L dithiothreitol (DTT), and 0.5mmol/L phenyl-
methylsulfonyl ﬂuoride (PMSF) (all from Sigma Chemical
Co., St. Louis, Mo, USA). The homogenates were incubated
on ice for 30 minutes and vortexed for 30 seconds after
addition of 50μL 10% NP-40 (Sigma Chemical Co., Mo,
USA). The mixture was then centrifuged for 10 minutes
(5000 × g, 4◦C). The pellet was suspended in 100μL ice-cold
buﬀer B composed of 50mmol/L HEPES pH 7.9, 50mmol/L
KCl, 300mM NaCl, 0.1mmol/L EDTA, 1mmol/LDTT, and
0.5mmol/L PMSF, and 10% (v/v) glycerol and incubated on
ice 30 minutes with frequent mixing. After centrifugation
(12000 × g, 4◦C) for 15 minutes, the supernatants wereWei Jin et al. 3
collected as nuclear extracts and stored at −70◦Cf o r
further use. Protein concentration was determined using a
bicinchoninic acid assay kit with bovine serum albumin as
the standard (Pierce Biochemicals, Rockford, Ill, USA).
EMSA was performed using a commercial kit (Gel Shift
Assay System; Promega, Madison, Wis, USA) following the
methods in our laboratory [23]. Consensus oligonucleotide
probe (5 -AGTTGAGGGGACTTTCCCAGGC-3 ) was end-
labeled with [γ-32P]ATP (Free Biotech., Beijing, China)
with T4-polynucleotide kinase. Nuclear protein (10μg)
was preincubated in a total volume of 9μL in a binding
buﬀer, consisting of 10mmol/L Tris-HCl (pH 7.5), 4%
glycerol,1mmol/LMgCl2,0.5mmol/LMEDTA,0.5mmol/L
DTT, 0.5mmol/L NaCl, and 0.05g/L poly-(deoxyinosinic-
deoxycytidylic acid) for 15 minutes at room temperature.
After addition of the 1μL 32P-labled oligonucleotide probe,
the incubation was continued for 20 minutes at room tem-
perature. Reaction was stopped by adding 1μL of gel loading
buﬀer and the mixture was subjected to nondenaturing 4%
polyacrylamide gel electrophoresis in 0.5 × TBE buﬀer (Tris-
borate-EDTA). After electrophoresis was conducted at 390V
for 1 hour, the gel was vacuum-dried and exposed to X-
ray ﬁlm (Fuji Hyperﬁlm, Tokyo, Japan) at −70◦Cw i t ha n
intensifying screed. Levels of NF-κB DNA binding activity
were quantiﬁed by computer-assisted densitometric analysis.
2.4. ELISAanalysis
Frozen brain samples were homogenized in 1mL of buﬀer
containing1mmol/LofPMSF,1mg/LofpepstatinA,1mg/L
of aprotinin, and 1mg/L of leupeptin in PBS solution (pH
7.2) with a glass homogenizer and then centrifuged at
12000g for 20 minutes at 4◦C. The supernatant was then
collected and total protein was determined by the Bradford
method. The levels of inﬂammatory cytokines were quan-
tiﬁed using enzyme-linked immunosorbent assay (ELISA)
kits speciﬁc for mouse according to the manufacturers’
instructions (TNF-α from Diaclone Research, France; IL-
1β,I L - 6f r o mB i o s o u r c eE u r o p eS A ,B e l g i u m )a n dp r e v i o u s
study of our laboratory [24]. The cytokine contents in the
brain samples were expressed as pg per milligram protein.
2.5. Immunohistochemicalstaining
The paraﬃn-embedded sections (4μm) were used for
Immunohistochemical assay, which was performed with a
goat antimouse ICAM-1(CD54) antibody (diluted 1:200,
R&D Systems, Inc., Minn, USA), according to previous stud-
ies of our laboratory [7]. The sections were incubated with
the diluted antibody overnight at 4◦C in a humid chamber,
washed,andblockedwith1.6% H2O2 inphosphate-buﬀered
saline (PBS) for 10 minutes. After washing with PBS again,
sections were then incubated with biotinylated second anti-
bodies for 1 hour at room temperature. Diaminobenzidine
(DAB) was used as chromogen and counterstaining was
done with hematoxylin. The number of positive microvessels
in each section was counted in 10 microscopic ﬁelds (at
100 × magniﬁcations) and averaged for the positively
immunostained vessel number of per visual ﬁeld.
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Figure 2: NF-κB activity in the cortex of sham and injured Nrf2
(+/+) and Nrf2 (−/−) mice. (a) Nuclear proteins of brain samples
of Nrf2 (+/+) and Nrf2 (−/−) mice were assayed for NF-κBD N A
binding activity by EMSA 24 hours after TBI. (b) Quantiﬁcation
of NF-κB DNA binding activity was performed by densitometric
analysis. The ﬁgure indicates that cerebral NF-κBa c t i v i t yw a s
signiﬁcantly increased afterTBIand was greater inNrf2(−/−)mice
than in Nrf2 (+/+) mice. Data represents mean ± SEM (n = 5
per group). ∗∗P<. 01 versus sham control of the same genotype.
##P<. 01 versus injured wild-type mice.
2.6. Statisticalanalysis
Software SPSS 13.0 was used for the statistical analysis.
A l ld a t aw e r ee x p r e s s e da sm e a n± SEM, Student’s t-test
was used to analyze the diﬀerences between the sham and
TBI groups within a single genotype as well as between
genotypes. Statistical signiﬁcance was accepted at P<. 05.
3. RESULTS
3.1. EMSAforNF-κB
NF-κB activation in the nuclear extracts was assessed by
EMSA. As shown in Figure 2,l o wN F - κB banding activity4 Mediators of Inﬂammation
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Figure 3: Concentrations of inﬂammatory cytokines in the cortex of sham and injured Nrf2 (+/+) and Nrf2 (−/−) mice. Concentrations of
(a) TNF-α,( b )I L - 1 β, and (c) IL-6 were determined by ELISA in the brain samples of Nrf2 (+/+) and Nrf2 (−/−) mice 24 hours after TBI.
The ﬁgure indicates that concentrations of TNF-α,I L - 1 β, and IL-6 in brain were signiﬁcantly increased after TBI and were greater in Nrf2
(−/−) mice than in Nrf2 (+/+) mice. Data represents mean ± SEM (n = 5 per group). ∗∗P<. 01 versus sham control of the same genotype.
#P<. 05 and ##P<. 01 versus injured wild-type mice.
(weak EMSA autoradiography) was observed in sham-
operated mice of both genotypes. TBI induced activation of
NF-κBinthecortexofbothNrf2(+/+)andNrf2(−/−)mice.
Nrf2 (−/−) mice showed an increased susceptibility to TBI-
induced activation of NF-κB than their wild-type Nrf2 (+/+)
counterparts.
3.2. ELISAforinﬂammatorycytokines
Concentrations of TNF-α,I L - 1 β, and IL-6 in the brain
samples were measured by ELISA. As shown in Figure 3,
low concentrations of TNF-α,I L - 1 β, and IL-6 were observed
in sham-operated mice of both genotypes. TBI induced
upregulation of TNF-α,I L - 1 β, and IL-6 in the cortex of both
Nrf2 (+/+) and Nrf2 (−/−)m i c e .N r f 2( −/−) mice showed
l a r g e ri n c r e a s ei nc o r t i c a ll e v e l so fT N F - α,I L - 1 β,a n dI L - 6
than their wild-type Nrf2 (+/+) littermates after TBI.
3.3. ImmunohistochemistryforICAM-1
For assessment of the expression of ICAM-A in the brain
after TBI, immunohistochemical study for ICAM-1 was per-
formed. As shown in Figure 4, few ICAM-1-immunostained
cerebral microvessels were observed in sham-operated mice
of both genotypes. At the 24 hours after TBI, the number
of ICAM-1 positive vessels was signiﬁcantly increased in
the cortex of both Nrf2 (+/+) and Nrf2 (−/−)m i c e .N r f 2
(−/−) mice showed larger increase in the number of ICAM-
1 positive vessels than their wild-type Nrf2 (+/+) littermates
after TBI.
4. DISCUSSION
The most important ﬁnding of this study is that Nrf2
(−/−) mice had more inﬂammatory cytokines TNF-α,I L -
1β and IL-6 production, ICAM-1 expression, and their
mediator NF-κB activation in brain after TBI compared
with their wild-type Nrf2 (+/+) counterparts. These ﬁndings
reported here suggest for the ﬁrst time that Nrf2 may play
an important role in limiting the cerebral inﬂammatory
responseafterTBIthroughmodulatingtheproinﬂammatory
nuclear factor kappa B (NF-κB) signaling pathway.
Activation of NF-κB signaling pathway has been shown
to be central to the pathophysiology of cerebral inﬂamma-
tory response induced by TBI [6, 7]. NF-κBc a nb ea c t i v a t e d
by lesion-induced oxidative stress, bacterial endotoxin, and
cytokines [25]. The functional importance of NF-κBi n
inﬂammationisbasedonitsabilitytoregulatethepromoters
of multiple inﬂammatory genes, including TNF-α,I L - 1 β,I L -
6, and ICAM-1 [4]. TNF-α is reported to be a major initiator
of inﬂammation and is released early after an inﬂammatory
stimulus [26]. IL-1β is regarded as the prototypic “mul-
tifunctional” cytokine and is induced in a multitude of
consequences of cell types [27]. IL-6 is increased after TNF-
α and is considered to be an important proinﬂammatory
cytokine in contribution to both morbidity and mortality
in condition of “uncontrolled” inﬂammation [28]. ICAM-1,
a member of the immunoglobulin superfamily which can
be profound induced after cytokine challenge, is important
in the recruitment of leukocytes during the inﬂammatory
process [29]. This inﬂammatory agent network is believed
to be important in the generation of acute inﬂammatory
response. NF-κB activation enhances the transcription of
proinﬂammatory cytokines, and the cytokines are known to
in turn activate NF-κB[ 5]. The positive feedback is believed
to serve to amplify inﬂammatory signals and exacerbate
brain injury after TBI. In the present study, we evaluated
the inﬂuence of Nrf2 genotype in the TBI-induced activation
of proinﬂammatory NF-κB signaling pathway in the brain.
The results showed that disruption of Nrf2 in mice caused aWei Jin et al. 5
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Figure 4: Expression of ICAM-1 in the cortex of sham and injured Nrf2 (+/+) and Nrf2 (−/−) mice. Immunohistochemical staining for
ICAM-1 was performed in the cortex tissue sections of Nrf2 (+/+) and Nrf2 (−/−) mice 24 hours after TBI. (a), (c) Sham-operated Nrf2
(+/+) and Nrf2 (−/−) mice showing few ICAM-1-immunostained cerebral microvessels. (b) Injured Nrf2 (+/+) mice showing increased
number of ICAM-1 positive vessels. (d) Injured Nrf2 (−/−) mice showing larger increment in the number of ICAM-1 positive vessels
compared with injured Nrf2 (+/+) mice. (e) Quantitative analysis showed that the number of ICAM-1 positive vessels in brain was
signiﬁcantly increased after TBI and was greater in Nrf2 (−/−) mice than in Nrf2 (+/+) mice. Data represents mean ± SEM (n = 5p e r
group). ∗∗P<. 01 versus sham control of the same genotype. #P<. 05 versus injured wild-type mice.
greateractivationofNF-κBsignalingpathwaywhichplayeda
critical role in the pathophysiology of cerebral inﬂammatory
response induced by TBI. The observed interplay between
Nrf2 and NF-κB signaling corresponds well to the results of
study on experimental sepsis, which have demonstrated that
Nrf2-deﬁcient mice displayed increased NF-κBa c t i v a t i o ni n
response to lipopolysaccharide (LPS) [19].
Although numerous in vivo studies have reported that
Nrf2 plays a critical role in counteracting the inﬂammation
in a variety of experimental models [14–19], the ﬁndings
which we have conﬁrmed and extended in the model of
TBI in the present study, the precise mechanism underlying
this network is still unclear. Several lines of evidence suggest
that Nrf2 regulates the inﬂammatory response by inhibiting
proinﬂammatory NF-κB activation through maintenance of
redox homeostasis. Oxidative stress from reactive oxygen
species (ROS) is believed to be involved in the progression of
secondary brain injury following TBI [30]. Activation of the
NF-κB signaling pathway has been shown to be responsive
to excess ROS and is important in the generation of inﬂam-
mation [19]. Nrf2, as a key antioxidant transcription factor
involved in the intracellular antioxidant defense systems, has
been shown to play an important role in limiting ROS levels
and thereby aﬀect redox-sensitive NF-κB signaling pathway
involved in the inﬂammation [8, 10–12]. The protective
function of Nrf2 is mainly mediated by a group of Nrf2-
regulated antioxidant and detoxifying enzymes. Therefore,
the augmentation of cellular antioxidative or detoxiﬁcation
systems via activation of Nrf2-regulated enzymes resulting
in decreased proinﬂammatory cytokines production and
adhesion molecules expression via inactivation of NF-κB
represents a possible anti-inﬂammatory mechanism for the
attenuated inﬂammatory response seen in brains from Nrf2
(+/+) mice but not Nrf2 (−/−) mice after TBI. We then in
this study postulated that Nrf2 regulates the TBI-induced
cerebral inﬂammatory response may at least in part through6 Mediators of Inﬂammation
modulating the cerebral redox status and proinﬂammatory
NF-κB signaling pathway. Additional work is necessary to
elucidate the whole mechanisms involved in these compli-
cated networks.
In summary, this present study showed that Nrf2 plays
a protective role in TBI-induced cerebral upregulation of
inﬂammatory agents in mice. We found that Nrf2 (−/−)
mice are more susceptible to TBI-induced cerebral NF-κB
activation, inﬂammatory cytokine TNF-α,I L - 1 β and IL-
6 production, and ICAM-1 expression, which then con-
tributed to exacerbated brain injury after TBI. To the best
of our knowledge, this is the ﬁrst study that elucidates
the interplay between Nrf2 and proinﬂammatory NF-κB
signaling pathway in the brain following TBI. These ﬁndings
raise the possibility that Nrf2 will be a new therapeutic target
for the treatment TBI.
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